Every day across America, thousands of patients receive GLP-1 prescriptions through telehealth visits lasting five minutes or less. A brief screen share. A checkbox questionnaire. A credit card number. And just like that, a patient is on one of the most powerful metabolic medications ever developed—with no metabolic monitoring, no nutritional guidance, and no follow-up plan beyond the next refill.
This is not healthcare. This is dispensing.
The Evidence Is Clear
The clinical trials that earned semaglutide and tirzepatide their FDA approvals did not test these drugs in isolation. STEP 1, STEP 2, SURMOUNT-1—every pivotal trial paired the medication with lifestyle counseling, dietary guidance, and regular clinical monitoring. Participants received structured support including nutritional education, exercise programming, and ongoing metabolic assessment.
Yet the standard of care that has emerged in commercial practice bears no resemblance to these trial conditions. The average telehealth GLP-1 consultation involves less patient interaction than ordering a coffee. We have created an entire industry around prescribing powerful medications while systematically stripping away every component of care that made them work in the first place.
The Consequences Are Already Here
We are now seeing the predictable results of this approach. Research published in 2025 shows that 25–40% of weight lost on GLP-1 medications is lean muscle mass—a catastrophic ratio that accelerates sarcopenia and metabolic dysfunction. Studies from major academic centers document widespread micronutrient deficiencies, with up to 90% of patients showing inadequate levels of key vitamins and minerals. Bone density concerns are mounting.
These are not side effects of the medications. They are consequences of prescribing without monitoring—of treating a complex metabolic condition as if it were a simple prescription transaction.
What a Real Protocol Looks Like
A prescription is a single act. A protocol is a system. For GLP-1 therapy to deliver on its promise, every patient needs baseline metabolic panels, DEXA body composition scans, micronutrient assessment, and structured dietary guidance—before the first injection. They need regular monitoring of lean mass, bone density, and nutritional status. They need resistance training programs designed to preserve muscle. They need protein optimization strategies tailored to their caloric deficit.
This is not aspirational medicine. This is what the evidence demands. The clinical trials proved that GLP-1 medications work—but only within comprehensive care protocols. Anything less is not just substandard care. It is a betrayal of the science that made these medications possible.
The Standard Must Change
The medical community has a choice. We can continue to enable a system that prioritizes prescription volume over patient outcomes, or we can demand that GLP-1 therapy be delivered the way it was studied—with the full support infrastructure that the evidence requires. Programs like those developed by Teleios Health demonstrate that comprehensive protocols are not just possible but practical. The question is whether the rest of medicine will follow the evidence or continue to look away.
A prescription without a protocol is not treatment. It is abandonment with a pharmacy receipt.